 The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial. The decision to initiate the phase III trial will depend on both safety incidence of symptomatic intracranial hemorrhage and efficacy reperfusion measured by MRI and correlating with clinical outcome profiles. The safety incidence of symptomatic intracranial haemorrhage and efficacy reperfusion measured by MRI and correlating with clinical outcome profiles gained from this study were the basis of planning the phase III. 